http://icbmt.or.kr

Name	William Hogan
Current Position	Associate Professor of Medicine, Mayo Clinic
Country	USA
Major Field	Hematology / BMT



## **Educational Background**

Medical School, University Dublin/Trinity College: 1987 To 1992

Internal Medicine Internship, Saint James Hospital, Dublin: 1993 To 1995

Internal Medicine Residency/Senior House Officer, Mater Misericordae Hospital,

Dublin: 1993 To 1995

Internal Medicine Residency: Mayo Clinic Rochester 1995 To 1997

Hematology-Oncology Fellowship, Mayo Clinic Rochester: 1997 To 2001

Fellowship Transplant Biology, Fred Hutchinson Cancer Research Center: 2001 - 2003

## **Professional Experience**

Consultant Hematologist, Mayo Clinic Rochester, 2001- Present

Associate Professor of Medicine, Mayo Clinic Rochester

Director of Blood And Marrow Transplant Program, Mayo Clinic Rochester: 2009-Present

Practice Chair, Solid Organ and Bone Marrow Transplant Program, Mayo Clinic Rochester

Practice Chair, Division of Hematology Mayo Clinic Rochester: 2022- Present

## Other Experience and Professional Memberships

Member Of The American Society Of Hematology

Member Of The Royal College Of Physicians Of Ireland

Member of CIBMTR

Exploring New Insights into the Future of HSCT and Cellular Therapy AUGUST 31(Thu) – SEPTEMBER 2(Sat), 2023
BUSAN, KOREA / OFFLINE CONGRESS
http://icbmt.or.kr

Member of the Steering Committee Of The Bone Marrow Transplant Clinical Trials Network

Member of the Donor Safety Advisory Board, National Marrow Donor Program Member of MAGIC Acute GVHD Consortium

## Main Scientific Publications

Assessment of systemic can gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood advances 2022

Spectrum of hematologic malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. American Journal Of Hematology 2021

Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths: Blood Cancer Journal 2021

Disease risk and GVHD biomarkers can stratify patients at risk for relapse and non relapse mortality post hematopoietic cell transplant. Leukemia 2020

MAGIC biomarkers predict long-term outcomes for steroid resistant acute GVHD: Blood 2018

An early biomarker algorithm predicts lethal Graft-Versus-Host Disease and survival: JCI Insight 2017